Adaptive Biotechnologies Co. (NASDAQ:ADPT) President Julie Rubinstein Sells 15,000 Shares


Share on StockTwits

Adaptive Biotechnologies Co. (NASDAQ:ADPT) President Julie Rubinstein sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 12th. The shares were sold at an average price of $62.69, for a total value of $940,350.00. Following the transaction, the president now owns 15,000 shares of the company’s stock, valued at approximately $940,350. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Julie Rubinstein also recently made the following trade(s):

  • On Friday, January 8th, Julie Rubinstein sold 8,814 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $60.46, for a total value of $532,894.44.
  • On Wednesday, January 6th, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $54.89, for a total value of $823,350.00.
  • On Monday, January 4th, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $57.17, for a total value of $857,550.00.
  • On Monday, December 28th, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $61.58, for a total value of $923,700.00.
  • On Wednesday, December 30th, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $59.61, for a total value of $894,150.00.
  • On Thursday, December 24th, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $63.53, for a total value of $952,950.00.
  • On Tuesday, December 22nd, Julie Rubinstein sold 15,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $63.71, for a total value of $955,650.00.

Shares of NASDAQ:ADPT traded up $1.03 during trading hours on Wednesday, hitting $63.49. 699,081 shares of the company’s stock traded hands, compared to its average volume of 685,232. Adaptive Biotechnologies Co. has a 1 year low of $15.19 and a 1 year high of $65.69. The business has a fifty day moving average price of $55.87 and a 200-day moving average price of $47.45. The firm has a market capitalization of $8.68 billion, a P/E ratio of -66.83 and a beta of 0.35.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Sunday, November 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. Adaptive Biotechnologies had a negative return on equity of 20.15% and a negative net margin of 132.32%. The business had revenue of $26.30 million during the quarter, compared to analyst estimates of $23.58 million. During the same quarter in the previous year, the business earned ($0.11) earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. On average, analysts predict that Adaptive Biotechnologies Co. will post -1.08 EPS for the current year.

Several institutional investors have recently bought and sold shares of ADPT. HM Payson & Co. bought a new stake in shares of Adaptive Biotechnologies during the third quarter valued at approximately $30,000. American International Group Inc. raised its stake in shares of Adaptive Biotechnologies by 39.8% during the second quarter. American International Group Inc. now owns 1,946 shares of the company’s stock valued at $94,000 after acquiring an additional 554 shares in the last quarter. AdvisorNet Financial Inc bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $109,000. Point72 Hong Kong Ltd bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $210,000. Finally, Neo Ivy Capital Management raised its stake in shares of Adaptive Biotechnologies by 753.0% during the third quarter. Neo Ivy Capital Management now owns 4,342 shares of the company’s stock valued at $211,000 after acquiring an additional 3,833 shares in the last quarter. 80.80% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently commented on the company. BTIG Research lifted their price target on Adaptive Biotechnologies from $60.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $60.00 price target (up previously from $50.00) on shares of Adaptive Biotechnologies in a research report on Wednesday, November 11th. Zacks Investment Research lowered Adaptive Biotechnologies from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Morgan Stanley boosted their target price on Adaptive Biotechnologies from $42.00 to $46.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $54.67.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals.

Featured Story: Risk Tolerance

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.